SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 17, 2025 / Bora Biologics is set to showcase its innovative Allosteric Formulation Platform at the Festival of Biologics 2025, demonstrating ...
WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and ...
Cytovance Biologics, a U.S.-based Contract Development and Manufacturing Organization (CDMO), announced the launch of its in-house formulation development services, significantly expanding its service ...
HanchorBio and WuXi Biologics collaborate to develop fusion proteins using the Fc-Based Designer Biologics platform, targeting oncology and autoimmune diseases. WuXi Biologics offers end-to-end ...
The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to enable concentrations up to 230 mg/mL It reduces viscosity by up to 90% while maintaining formulation ...
Adds to Drug Product Aseptic Formulation Development Expertise and Drug Product Manufacturing ALBANY, N.Y.–(BUSINESS WIRE)–July 13, 2021– Curia, formerly AMRI, a leading contract research, development ...
WOBURN, Mass.--(BUSINESS WIRE)--ReForm Biologics, a pharmaceutical technology company developing innovative biologic formulations to improve drug delivery and manufacturing, expanded its patent ...
WOBURN, Mass.--(BUSINESS WIRE)--ReForm Biologics, a pharmaceutical technology company developing innovative biologic formulations to improve drug delivery and manufacturing, today announced a new ...
Press Trust of India on MSN
WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline
SHANGHAI, Jan ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results